Rezolute, Inc. (Nasdaq: RZLT) presented four data analyses at the Annual Meeting of the Endocrine Society, covering natural history outcomes in congenital hyperinsulinism (HI) and clinical results from its ersodetug program.

Two poster presentations examined the natural history and adverse outcomes of congenital HI, using a meta-analysis of existing literature and a claims-based analysis to quantify disease complications. A third poster reported results from a case series of nine patients with refractory hypoglycemia due to malignant insulinoma and non-islet cell tumors enrolled in the company's Expanded Access Program. According to the press release, 75% of those patients receiving intravenous dextrose or total parenteral nutrition achieved complete discontinuation of that therapy.

A fourth presentation, delivered orally by Huseyin Demirbilek, M.D., Professor of Pediatric Endocrinology at Hacettepe University in Ankara, Turkey, reviewed previously reported results from Rezolute's Phase 3 sunRIZE study of ersodetug in congenital HI. Dr. Demirbilek served as principal investigator of that study.

Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor, aimed at reducing receptor over-activation in HI settings. Rezolute is also conducting a Phase 3 study called upLIFT in tumor HI patients.

"Deeper analyses of the sunRIZE data demonstrate the meaningful therapeutic benefit of ersodetug, further supported by the positive outcomes observed in both our EAP and recently announced interim and preliminary Phase 3 upLIFT study observations in tumor HI patients," said Brian Roberts, M.D., Chief Medical Officer of Rezolute.